索拉非尼不良事件个体化剂量管理延长肝细胞癌患者生存
基于意大利3个三级中心2008—2017年前瞻性连续收集的338例索拉非尼治疗肝细胞癌患者,按起始年份分为A组(2008—2012年,n=154)与B组(2013—2017年,n=184)。B组因更频繁调整剂量而中位日剂量更低(425 vs 568 mg/天,p<0.001),但治疗时间更长(5.8 vs 4.1个月,p=0.021)、总生存更高(12.0 vs 11.0个月,p=0.003),2年生存率亦更高(28.1% vs 18.4%,p=0.003)。
要点
- B组中位日剂量425 mg/天低于A组568 mg/天(p<0.001),源于更频繁的剂量调整。
- B组治疗时间5.8个月长于A组4.1个月(p=0.021),总生存12.0个月亦长于A组11.0个月(p=0.003)。
- 多因素时间依赖Cox回归显示2013—2017年治疗期为生存独立预测因素(HR 0.728;95%CI 0.581-0.937;p=0.013)。
核心结论
- 索拉非尼相关不良事件管理经验可延长治疗时间与生存,未来含索拉非尼组的随机临床试验设计应考虑到该因素,否则可能低估样本量。
研究设计与样本
- 分析意大利3个三级中心2008年1月至2017年12月连续开始索拉非尼治疗的前瞻性收集数据,共338例患者。
- 按起始日期分为A组(2008—2012年,n=154)与B组(2013—2017年,n=184),比较基线与随访数据。
- 总生存分析中,接受二线治疗的患者在开始新治疗时删失。
主要发现
- 两组基线特征、不良事件及影像学缓解一致。
- B组中位日剂量425 mg/天低于A组568 mg/天(p<0.001),因剂量调整更频繁。
- B组治疗时间5.8个月长于A组4.1个月(p=0.021),累积剂量呈更高趋势。
- B组总生存12.0个月高于A组11.0个月(p=0.003),2年生存率28.1%高于A组18.4%(p=0.003)。
- 多因素时间依赖Cox回归显示2013—2017年治疗期为生存独立预测因素(HR 0.728;95%CI 0.581-0.937;p=0.013),敏感性分析示未考虑混杂因素不太可能影响结果。
关键数值与推荐
- B组中位日剂量425 mg/天 vs A组568 mg/天(p<0.001)。
- B组治疗时间5.8个月 vs A组4.1个月(p=0.021)。
- B组总生存12.0个月 vs A组11.0个月(p=0.003)。
- B组2年生存率28.1% vs A组18.4%(p=0.003)。
- 2013—2017年治疗期预测生存的HR 0.728(95%CI 0.581-0.937;p=0.013)。
临床怎么用
- 对索拉非尼相关不良事件进行积极管理并个体化调整剂量,可能延长治疗时间并改善生存。
- 设计含索拉非尼治疗臂的未来随机临床试验时,应考虑不良事件管理经验对样本量估计的影响。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Sorafenib is associated with multiple adverse events (AEs), potentially causing its permanent interruption. It is unknown how physicians' experience has impacted on the management of these AEs and consequently on clinical outcomes. We aimed to assess whether AE management changed over time and if these modifications impacted on treatment duration and overall survival (OS). METHODS: We analysed the prospectively collected data of 338 consecutive patients who started sorafenib between January 2008 and December 2017 in 3 tertiary care centres in Italy. Patients were divided according to the starting date: Group A (2008-2012; n = 154), and Group B (2013-2017, n = 184). Baseline and follow-up data were compared. In the OS analysis, patients who received second-line treatments were censored when starting the new therapy. RESULTS: Baseline characteristics, AEs, and radiological response were consistent across groups. Patients in Group B received a lower median daily dose (425 vs. 568 mg/day, p <0.001) due to more frequent dose modifications. However, treatment duration was longer (5.8 vs. 4.1 months, p = 0.021) with a trend toward a higher cumulative dose in Group B. Notably, the OS was also higher (12.0 vs. 11.0 months, p = 0.003) with a sharp increase in the 2-year survival rate (28.1 vs. 18.4%, p = 0.003) in Group B. Multivariate time-dependent Cox regression analysis confirmed later period of treatment (2013-2017) as an independent predictor of survival (HR 0.728; 95%CI 0.581-0.937; p = 0.013). Unconsidered confounders were unlikely to affect these results at the sensitivity analysis. CONCLUSIONS: Experience in the management of sorafenib-related AEs prolongs treatment duration and survival. This factor should be considered in the design of future randomised clinical trials including a sorafenib treatment arm, as an underestimate of sample size may derive. LAY SUMMARY: Sorafenib has been the standard frontline systemic treatment for hepatocellular carcinoma for over a decade. Its tolerability is limited by different adverse events, which might lead to its permanent discontinuation in a sizeable proportion of patients. After a careful analysis of potential confounders, we demonstrated that the physicians' experience in managing adverse events related to sorafenib has improved over time, with longer treatment periods and less permanent discontinuation for toxicities. More importantly, these improvements also translated into longer patient survival. Our results have relevant repercussions in clinical practice and in the design of future clinical trials.
引用
- Tovoli F, Ielasi L, Casadei-Gardini A, et al. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol. 2019. PMID: 31449860. doi:10.1016/j.jhep.2019.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。